Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 7/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 3/20 | 0.63 |
| ▸ | CA1 | P00915 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | CA12 | O43570 | 1/20 | 0.63 |
| ▸ | CA4 | P22748 | 1/20 | 0.63 |
| ▸ | CA6 | P23280 | 1/20 | 0.63 |
| ▸ | CA5A | P35218 | 1/20 | 0.63 |
| ▸ | CA7 | P43166 | 1/20 | 0.63 |
| ▸ | CA9 | Q16790 | 1/20 | 0.63 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.63 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Buthiazide SCHEMBL29364486 | 1.00 | TDP1 (0.76) | TDP1LMNAALDH1A1CYP2C9CYP1A2 | |
| Buthiazide SCHEMBL7357204 | 0.89 | TDP1 (0.61) | TDP1LMNAALDH1A1CYP2C9CYP1A2 | |
| Ethiazide SCHEMBL30561875 | 0.86 | TDP1 (1.00) | TDP1LMNAALDH1A1CYP2C9CYP1A2 | |
| Ethiazide SCHEMBL122238 | 0.86 | TDP1 (1.00) | TDP1LMNAALDH1A1CYP2C9CYP1A2 | |
| SCHEMBL13685945 | 0.85 | TDP1 (0.79) | TDP1LMNAALDH1A1CYP2C9CYP1A2 | |
| SCHEMBL29925887 | 0.84 | TDP1 (0.82) | TDP1LMNAALDH1A1CYP2C9CYP1A2 | |
| SCHEMBL11038368 | 0.84 | TDP1 (0.77) | TDP1LMNAALDH1A1CYP2C9CYP1A2 | |
| SCHEMBL29132639 | 0.84 | LMNA (0.79) | TDP1LMNAALDH1A1CYP2C9CYP1A2 | |
| SCHEMBL30561865 | 0.84 | LMNA (0.79) | TDP1LMNAALDH1A1CYP2C9CYP1A2 | |
| SCHEMBL13685954 | 0.83 | TDP1 (0.76) | TDP1LMNAALDH1A1CYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1759 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| US-20250057876-A1 | METHODS FOR TREATING AND/OR PREVENTING LYMPHANGIOGENESIS-ASSOCIATED DISEASES BY USING GOLD NANOCLUSTERS | GOLDRED NANOBIOTECH CO., LTD. (TW) | 2025-02-20 | — | — | US | claimed |
| US-20240002935-A1 | GENETIC METHOD FOR DIAGNOSIS AND TREATMENT OF PRE AND POST CORONAVIRUS INFECTIONS | GENETICURE INC. | 2024-01-04 | — | — | US | claimed |
| EP-4132653-A1 | GENETIC METHOD FOR DIAGNOSIS AND TREATMENT OF PRE AND POST CORONAVIRUS INFECTIONS | Geneticure Inc. (US) | 2023-02-15 | — | — | EP | claimed |
| US-10590485-B2 | Therapeutic regimen for hypertension | GENETICURE LLC (US) | 2020-03-17 | — | — | US | claimed |
| EP-3149487-B1 | IMPROVED THERAPEUTIC REGIMEN FOR HYPERTENSION | GENETICURE LLC (US) | 2020-02-12 | — | — | EP | claimed |
| US-20180195128-A1 | Therapeutic Regimen for Hypertension | GENETICURE INC. | 2018-07-12 | — | — | US | claimed |
| CN-107596375-A | A kind of drug compound preparation for treating hypertensive obesity patient and preparation method thereof | 郭裴哲 | 2018-01-19 | — | — | CN | claimed |
| US-20170079978-A1 | THERAPY FOR COMPLICATIONS OF DIABETES | ABBVIE DEUTSCHLAND (DE) | 2017-03-23 | — | — | US | claimed |
| US-20160287558-A1 | ORAL PHARMACEUTICAL FORM FOR PREVENTING VASCULAR DISEASES, TABLET AS PHARMACEUTICAL FORM AND GELATIN CAPSULE AS PHARMACEUTICAL FORM | HYPERMARCAS S.A. (BR) | 2016-10-06 | — | — | US | claimed |
| WO-1999025374-A1 | COMBINATION OF HYPERTENSIN CONVERTING ENZYME INHIBITOR WITH A DIURETIC FOR TREATING MICROCIRCULATION DISORDERS | ADIR ET COMPAGNIE (FR) | 1999-05-27 | — | — | WO | claimed |
| EP-0643580-A4 | COMBINATIONS OF ACE INHIBITORS AND DIURETICS. | — | 1995-04-19 | — | — | EP | claimed |
| EP-0643580-A1 | COMBINATIONS OF ACE INHIBITORS AND DIURETICS | MERCK & CO. INC. (US) | 1995-03-22 | — | — | EP | claimed |
| WO-1994009778-A1 | COMBINATIONS OF ANGIOTENSIN-II RECEPTOR ANTAGONISTS AND DIURETICS | MERCK & CO., INC. (US) | 1994-05-11 | — | — | WO | claimed |
| WO-1993017685-A1 | COMBINATIONS OF ACE INHIBITORS AND DIURETICS | MERCK & CO., INC. (US) | 1993-09-16 | — | — | WO | claimed |
| US-4855289-A | Combination of two active substances | WESTER PER O (SE) | 1989-08-08 | — | — | US | claimed |
| US-4557934-A | ALONG WITH A DIOL PYRROLIDONE OR AN AZACYCLOPENTAN-2-ONE | THE PROCTER & GAMBLE COMPANY (US) | 1985-12-10 | — | — | US | claimed |
| US-4238485-A | 1,2,5-THIADIAZOLE DERIVATIVE, THIAZIDE DIURETIC, HYPOTENSIVE AGENTS | MERCK & CO., INC. (US) | 1980-12-09 | — | — | US | claimed |
| US-4178374-A | SUBSTITUTED 1,2,5-THIADIAZOLE B-ADRENERGIC BLOCKING AGENT, PYRAZINE AND/OR THIAZIDE DIURETIC, TREATMENT OF HYPERTENSION | MERCK & CO., INC. (US) | 1979-12-11 | — | — | US | claimed |
| US-4075335-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1978-02-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170079978-A1 | THERAPY FOR COMPLICATIONS OF DIABETES | EDNRA, EDNRB, GPR119 | TDP1 2371/4885LMNA 2132/4885ALDH1A1 3904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.